BioSignal

Concise biotech intelligence. Oncology, cell therapy, antibodies, ADCs, gene therapy, and early clinical signals. High signal, low noise.

[BioSignal @BioSignal]

Biotech M&A is broken. The historical playbook was simple: a startup creates an incredible asset, and a multinational pharma company (MNC) swallows them whole to run the commercial launch. But the top-tier biotechs are now refusing to be acquired—and they are poaching Big Pharma's crown jewels to build their own global empires.

Earlier this year, Merck ($MRK) offered a massive $32B to acquire Revolution Medicines ($RVMD) for their pan-RAS oncology pipeline. Revolution flatly rejected the buyout.

Now, the story gets wild. Not only did Revolution refuse the acquisition, but they just poached Thomas Lampron—Merck’s Global VP of Oncology Marketing and one of the core architects behind Keytruda’s historic commercial scale-up.

The move signals that the pan-RAS field is officially transitioning from an early-stage science story into aggressive commercial execution. At ASCO 2026, Revolution's lead asset daraxonrasib demonstrated a median Overall Survival (mOS) of 13.2 months vs 6.7 months for chemotherapy in pancreatic cancer—effectively doubling survival in a historical regulatory graveyard.

Instead of passing the baton to an MNC, Revolution is keeping the economics and assembling a heavy-hitting commercial team to launch daraxonrasib independently. For Merck, losing the acquisition target was a strategic setback; losing their elite oncology marketing talent to that same target is a brutal validation of changing power dynamics.

This is the pipeline to watch. 🧵

$RVMD $MRK $AMGN $BMY $XBI $IBB

[BioSignal @BioSignal]

Spinal cord injury (SCI) has long been the graveyard of regenerative medicine, where early-stage cell therapies frequently stalled due to a lack of clear regulatory pathways and standard manufacturing compliance. That paradigm is shifting as structural frameworks formalize a rapid route to the clinic.

China’s National Health Commission just approved its first neural cell therapy registry under the newly implemented "Decree 818" compliance framework. Private innovator Hongchen Bio secured the historic clearance for HCXY-001, an hPSC-derived GABAergic neural progenitor cell therapy targeting spinal cord injury.

Instead of generic mesenchymal stem cell infusions that flush out of the system with minimal localized effect, this platform relies on precisely differentiated GABAergic progenitors to address the local excitation/inhibition imbalance at the lesion site. By physically grafting into the damaged tissue and structurally rebuilding severed neural circuits, it targets root-cause motor, bladder, and sensory restoration.

While Western cell therapy players tackling spinal cord injury—like Lineage Cell Therapeutics ($LCTX) with its oligodendrocyte progenitor pipeline—have faced multi-year clinical timelines and rigid regulatory friction, China is leveraging this new standardized framework to rapidly advance neuro-regeneration assets into human trials. The regulatory gridlock in advanced cell therapy is officially clearing.

$LCTX $VRTX $XBI $IBB

[BioSignal @BioSignal]

Wall Street thinks Summit ($SMMT) is the only asset capable of dethroning Merck’s Keytruda in lung cancer. They are completely overlooking the defensive wall Merck ($MRK) just built using a different Chinese asset.

The primary threat to Keytruda's empire has been Akeso's ($9926 HK) PD-1/VEGF bispecific (ivonescimab), which just dropped massive ASCO 2026 data reducing the risk of death by 34% in 1L squamous NSCLC. But shifting the paradigm from single checkpoints doesn't require abandoning Keytruda. Combining a tumor-targeting ADC with a checkpoint inhibitor yields deep tumor debulking and antigen shedding, hitting the cancer from two completely distinct angles.

At ASCO, Merck's partner Kelun-Biotech ($6990 HK) dropped absolute monster data for their TROP2 ADC (sac-TMT) combined with Keytruda in 1L NSCLC:
• PFS Hazard Ratio: 0.35 (65% reduction in disease progression)
• OS Hazard Ratio: 0.55 (45% reduction in risk of death)

While Western analysts are actively debating whether Akeso’s data will replicate seamlessly across Western populations, Merck is leveraging Kelun's platform to fortify its multi-billion dollar franchise with superior combo data. The future of global oncology dominance isn't being built in Boston or Basel—it's being imported from China.

This is the pipeline to watch. 🧵

$MRK $SMMT $6990 HK $9926 HK $XBI $IBB

[BioSignal @BioSignal]

The real bottleneck in RNAi therapeutics isn't finding the right gene to silence—it's getting the drug out of the liver.

GalNAc technology successfully solved liver targeting, turning siRNA into a blockbuster modality for cardiovascular and rare metabolic diseases. But expanding RNAi to the kidneys, fat tissue, or the heart has been a delivery graveyard due to rapid renal clearance and complex physiological barriers. While Western pioneers like Alnylam ($ALNY) and Arrowhead ($ARWR) race to monopolize extrahepatic delivery, Chinese biotechs are quietly breaking the delivery monopoly.

Suzhou Ribo Life Science just unveiled preclinical and IND-enabling data for its proprietary RiboPepSTAR peptide-conjugate platform, demonstrating cross-species extrahepatic efficiency that matches or exceeds Western benchmarks.

Instead of fighting over crowded liver-targeted pipelines, Ribo is pivoting entirely to next-generation tissues:

• Kidney (SR103): Moving into IND as potentially the first siRNA targeting the renal proximal tubules for CKD and T2D. Data shows a kidney-to-liver enrichment ratio of several hundred-fold and an 80% target gene knockdown with zero renal toxicity.
• Adipose/Fat: In non-human primates (NHPs), a single 9mg/kg dose achieved >95% gene silencing in fat tissue, with efficacy lasting out to 85 days. This directly challenges Arrowhead’s ARO-ALK7 obesity pipeline.
• Myocardium: Achieved 80% gene knockdown in heart tissue at a low 1mg/kg dose, with near-zero off-target silencing in the liver or kidneys.

Big Pharma is already validating this shift—look at Lilly's ($LLY) $1.2B bio-buck deal with Sanegene or GSK’s ($GSK) recent metabolic deal with Starna. Ribo’s extensive 70+ patent wall around peptide-siRNA conjugation positions them as a prime target for the next massive multi-billion dollar extrahepatic platform BD deal.

The era of liver-only RNAi is ending, and the extrahepatic land grab is moving faster in the East than Wall Street realizes.

This is the pipeline to watch. 🧵

$ALNY $ARWR $RNA $LLY $GSK $XBI $IBB

[BioSignal @BioSignal]

Most investors assume cell therapy for autoimmune diseases requires permanent, viral-vectored CAR-T cells. They are missing the shift toward transient, safer alternatives.

For oncology, CAR-T persistence is necessary to kill every tumor cell. But for autoimmune diseases like Lupus (SLE), you don't want permanent CAR-T cells lurking around and causing long-term immunosuppression. You just need a deep, temporary "immune reset."

Using mRNA delivered via lipid nanoparticles (LNPs) creates transient CAR-T cells in vivo. The engineered cells do their job, wipe out the pathogenic cells, and then the mRNA naturally degrades—entirely eliminating the risks of genomic integration or secondary malignancies.

CSPC Pharmaceutical ($1093.HK) just secured CDE approval for SYS6063, marking the world’s first mRNA-LNP dual-target (CD19/BCMA) CAR-T to enter the clinic for Lupus.

While Western biotechs are mostly focused on single-target CD19 ex-vivo therapies or early-stage in-vivo platforms, CSPC is skipping ahead by co-targeting CD19 (B cells) and BCMA (plasma cells) simultaneously. This hits both the mature B cells and the long-lived plasma cells producing the autoantibodies, offering a far more thorough reset of the immune system.

If this transient, off-the-shelf mRNA approach works in SLE, it completely de-risks the safety profile of cell therapy for non-oncology indications and challenges the asset valuations of single-target competitors.

This is the pipeline to watch. 🧵

$1093.HK $RNAC $CABA $KYVR $XBI $IBB

[BioSignal @BioSignal]

Everyone assumes the future of cell therapy relies on building massive, complex manufacturing facilities to scale production. The real alpha is bypassing the lab entirely and turning the patient's own body into the manufacturing factory.

Traditional CAR-T therapies are ex vivo: you extract T-cells, engineer them in a central lab for a month, and infuse them back. It creates severe bottlenecks, costs hundreds of thousands of dollars per patient, and requires harsh lymphodepletion. In vivo CAR-T changes the paradigm by using a targeted viral vector to deliver genetic instructions straight into the bloodstream, engineering the T-cells directly inside the patient.

Legend Biotech just released breakthrough Phase 1 data for their in vivo CAR-T (LB2501, CD19/CD20) ahead of EHA 2026, and the numbers are staggering.
• 100% ORR (Objective Response Rate)
• 83.3% CR (Complete Response)
• No lymphodepletion required
• 0% severe toxicities (No DLTs, no SAEs, no ICANS)

This is an "off-the-shelf" infusion that doctors can keep in a clinic fridge, reducing production costs to an estimated 1/10th of traditional CAR-T. If this data holds in larger trials, it completely disrupts the commercial and pricing models of every ex vivo cell therapy currently on the market. This is the pipeline to watch. 🧵

$LEGN $JNJ $XBI $IBB

[BioSignal @BioSignal]

The traditional biotech model of spending five to ten years burning cash in preclinical discovery is being actively bypassed. The new meta is geographic arbitrage: in-license de-risked, early-clinical assets from China, attach an elite Western management team, raise massive US capital, and go public.

Avenzo Therapeutics just executed this playbook flawlessly. They are going public via a reverse merger with Rallybio, backed by a concurrent $215M mega-PIPE from heavyweights like Blackstone, OrbiMed, and T. Rowe Price.

With cash runway secured through 2028, Avenzo is set to run multiple Phase 1/2 trials. But the real alpha here is the origin of their pipeline. Avenzo is not a discovery company; it is a pure-play clinical execution engine. All four of their clinical-stage oncology assets were sourced directly from Chinese biotechs:

The CDK Portfolio (from Allorion Therapeutics): AVZO-021 (selective CDK2) and AVZO-023 (selective CDK4). Designed to tackle resistance to standard CDK4/6 inhibitors in HR+/HER2- breast cancer.

AVZO-1418 (from DualityBio): A first-in-class EGFR x HER3 bispecific ADC currently showing clinical activity across multiple solid tumors.

AVZO-103 (from VelaVigo): A Nectin4 x TROP2 bispecific ADC actively being evaluated for urothelial cancer and other solid tumors.

Led by veteran CEO Athena Countouriotis, Avenzo has effectively built a premium bridge between Chinese innovation and US capital markets. Wall Street's willingness to throw $215M at this exact model proves that the stigma around foreign-sourced assets is entirely dead, provided the clinical execution is handled by a trusted Western team.

This is the pipeline—and the business model—to watch. 🧵

$RLYB $XBI $IBB

[BioSignal @BioSignal]

Everyone is chasing standard CAR-Ts for oncology, but the next massive cell therapy alpha is in neurodegeneration via "AI + Chemical Induction."

Relying on traditional stem cell differentiation for Parkinson's is slow, expensive, and unpredictable. Using AI to map pathology, combined with targeted small-molecule cocktails to chemically induce functional cells, entirely solves the scalable manufacturing bottleneck.

iRegene Therapeutics just quietly closed a ¥210M C1 round to take this exact platform global. They are pushing their chemically-induced cell therapies for Parkinson's and Multiple System Atrophy (NouvNeu001/004) into simultaneous US/China clinical trials. By bypassing traditional manufacturing hurdles, they are moving faster than Western neuro cell pipelines and aggressively de-risking the aging disease market, with retinal targets up next.

If this AI-driven cell replacement platform holds up in the clinic, it disrupts the entire neuro-restoration landscape. This is the pipeline to watch. 🧵

$BAYRY $RXRX $BIIB $NVS $XBI $IBB

[---- @Hu72094742]

Cell therapy is shifting to "off-the-shelf injectables." Imagine combining in vivo CAR-T with @ImmunityBio’s pipeline: one shot of in vivo CAR-T to target the cancer, paired with an IL-15 agonist ( Anktiva) to aggressively expand and sustain those newly formed T cells in vivo. 🚀

[Thoughts on Healthcare Markets and Tech @thoughtson_tech]

Manufacturing scalability was the unsolved half of this equation until very recently.

The clinical signal here is striking, but the question in vivo CAR-T has never fully answered is whether 100% ORR in 18 patients holds when you move from a controlled Phase 1 to the heterogeneous real-world population where ex vivo manufacturing failed first. The patients who couldn't wait weeks for cell processing, or whose T cells were too exhausted to expand.

When I was writing about in vivo CAR-T for my convergence piece, the mechanism that kept surfacing was enveloped delivery vehicles programming T cells directly, producing responses in mouse models comparable to ex vivo manufacturing. The promise was always that you'd collapse a weeks-long, hundreds-of-thousands-of-dollars workflow into something administered like a drug. Kelonia's Phase 1 data suggests that promise is materializing in humans, which is a different category of validation than preclinical work.

What I'm less certain about is whether the 80%+ experimental validation rates we're seeing from AI-designed protein-protein interactions, like what RFdiffusion achieved, are being systematically applied to the targeting construct design in programs like KLN-1010, or whether those tools are still operating downstream of the core clinical decisions.

The harder question this data raises: if in vivo CAR-T achieves durable remissions at scale, does that accelerate or complicate the case for next-generation closed-loop design platforms, given that the current generation may already be good enough for the indication?

https://t.co/AcJmyCszQK

[Dimitrios L. Wagner @dlwagner13]

@BioSignal … for established targets and CAR constructs. In vivo is a great way to democratize and improve access, once long term safety is established. Probably still not the platform to innovate new concepts for hard to treat cancers etc.

[BioSignal @BioSignal]

BREAKING: Abivax shares plummeted 44% today after P3 maintenance data for its Ulcerative Colitis (UC) drug, Obefazimod, revealed a glaring safety signal despite easily hitting all primary efficacy endpoints.

While the 44-week clinical remission rates were incredibly strong (51.3% for the 50mg dose vs. an ultra-low 10.4% placebo), the high-dose cohort reported 7 cases of malignancy. Obefazimod’s entire bull thesis—and the catalyst behind its massive run-up over the last year—was its positioning as a safer, novel-mechanism alternative to JAK inhibitors like AbbVie's Rinvoq. This cancer signal completely shatters that clean safety narrative. Even if it manages to secure NMPA and FDA approvals, the drug now faces a highly probable ODAC review and a severe black box warning. This effectively kills its front-line commercial prospects and throws serious cold water on the recent Eli Lilly buyout rumors.

$ABVX $ABBV $LLY $XBI $IBB

[BioSignal @BioSignal]

Chronic daily statins and even twice-a-year siRNAs for high cholesterol are about to become obsolete. The future of cardiovascular disease management is the "one-and-done" in vivo base editing paradigm.

Eli Lilly just dropped 18-month Phase 1b data for VERVE-102, an in vivo GalNAc-LNP base editor that permanently turns off the PCSK9 gene in the liver. A single 1.0 mg/kg infusion safely dropped LDL-C by 62%. The entire treatment landscape is officially shifting from chronic management to permanent genetic cures.

But Western giants don't own this space. Chinese biotechs are fast-following with highly competitive, clinical-stage Alpha. YaoTang Bio’s YOLT-101 is matching these efficacy signals at much lower doses, demonstrating a 52.3% LDL-C reduction at just 0.6 mg/kg. RuiZheng Gene’s ART002 just achieved a massive 90% PCSK9 protein knockdown in super-high baseline patients. Meanwhile, for next-gen lipid targets, CorrectSequence Therapeutics is leading the charge on APOC3 with CS-121, aiming for a one-time cure for severe hypertriglyceridemia.

This is the pipeline to watch. 🧵

$LLY $NVS $CRSP $ALNY $XBI $IBB

[BioSignal @BioSignal]

Big Pharma has long treated post-stroke chronic motor deficits as an irreversible write-off. Standard-of-care is just palliative physical therapy, and previous mesenchymal stem cell attempts like SanBio’s SB623 have faced massive commercial and clinical hurdles.

But a Chinese player just cracked the FDA's most exclusive advanced-modality fast track.

Zhejiang Hopestem just secured FDA Regenerative Medicine Advanced Therapy (RMAT) designation for hNPC01—marking the world’s first iPSC-derived forebrain neural progenitor cell therapy to win this status for ischemic stroke.

The underlying Phase 1 data across 20 chronic patients (6 months to 5 years post-stroke) justifies the FDA's urgency:
• 12-month mean FMMS (Fugl-Meyer Motor Scale) improved by a massive 16 points.
• At 18 months, 92% of participants achieved significant clinical improvement.
• 54% of patients dropped an entire disability grade, with wheelchair-dependent patients regaining the ability to stand and walk.

While major Western iPSC pioneers like Vertex ($VRTX), Sana ($SANA), and Lineage ($LCTX) focus their pipelines on diabetes, Parkinson's, or ophthalmology, Chinese biotech is quietly capturing the massive, unaddressed market of stroke-induced neuro-regeneration.

RMAT status unlocks rolling review, frequent FDA interaction, and a direct line to accelerated approval. This drastically de-risks the global thesis for iPSC-based CNS repair and sets Hopestem up as a prime candidate for a major cross-border BD out-licensing deal.

$VRTX $SANA $LCTX $BAYRY $XBI $IBB

[BioSignal @BioSignal]

BREAKING: Roche and Alnylam just secured NMPA Breakthrough Therapy Designation in China for their $2.8B RNAi hypertension drug, Zilebesiran.

Why it matters: The hypertension market is plagued by daily pill fatigue and poor compliance. Zilebesiran is a twice-a-year subcutaneous injection that shuts down liver AGT to sustainably lower blood pressure. Gaining Breakthrough status in China massively accelerates their regulatory timeline in the world’s largest cardiovascular market. Roche is projecting >3B CHF in peak sales and is currently running the massive 11,000-patient Phase 3 ZENITH trial. Their recent Phase 2 KARDIA-3 data already demonstrated a sustained reduction in systolic BP for up to 6 months, especially when combined with standard diuretics.

This is a massive signal that siRNA therapies are officially transitioning from niche rare diseases into blockbuster chronic indications. The paradigm for managing systemic high blood pressure is shifting from daily pills to semi-annual injectables.

$RHHBY $ALNY $NVS $XBI $IBB

[BioSignal @BioSignal]

BREAKING: Eli Lilly’s recently acquired Kelonia Therapeutics just dropped unprecedented Phase 1 data at ASCO for their in vivo BCMA CAR-T (KLN-1010).

18 patients with R/R Multiple Myeloma showed a 100% ORR and 100% MRD negativity at 1 month.

Why it matters: This is a direct infusion. Zero lymphodepleting chemo pre-conditioning required. Zero manufacturing wait times. If these numbers hold, in vivo CAR-T will completely obliterate the commercial moat of traditional ex vivo CAR-Ts like Carvykti and Abecma.

Chinese innovators are already fast-following this Alpha: Weitao Bio and Hongxin Bio just reported their own early clinical validation for mRNA-LNP in vivo CAR-Ts in Lymphoma and Lupus (SLE). The entire cell therapy paradigm is shifting to off-the-shelf injectables.

$LLY $LEGN $JNJ $BMY $AZN $XBI $IBB

[Digital Epoch @TheDigitalEpoch]

@BioSignal CD8+ T cell residency in the dermis is the relapse engine that symptom-focused therapies keep missing. By 2035, CRISPR-based Trm modulation could make vitiligo one of the first autoimmune conditions with a genuinely durable cure.

[Digital Epoch @TheDigitalEpoch]

@BioSignal The $370K ex vivo price tag is basically the market screaming for in vivo, and China's regulatory scientists just handed everyone the roadmap.

[BioSignal @BioSignal]

ASCO 2026 is over. Three readouts will move more market cap than the other ~5,000 abstracts combined — and only two of them reset a backbone.

1. daraxonrasib (RASolute 302): OS 13.2 vs 6.7, HR 0.40, 2L pancreatic. A standard of care where there wasn't one. Backbone reset.
2. sac-TMT + pembro (OptiTROP-Lung05): PFS not reached vs 5.7, HR 0.35, 1L PD-L1+ NSCLC. First ADC+IO to win first-line. Backbone reset.
3. adjuvant selpercatinib (LIBRETTO-432): EFS positive in RET+ early NSCLC. Real, but narrow — small biomarker slice, OS immature. A one-setting win until OS matures.

The tell across all three: plenary data reprices comps asset-by-asset, not sector-wide. Watching which partnered programs move off these three.

[Scofiled @Scofiled0369]

@BioSignal 现在这个阶段AIDD只能优化药物的安全性，提高候选化合物的筛选效率，要么就纯粹的平台服务像SDGR，要么就做Biotech按管线估值